Scaling Cultured Meat: Challenges and Solutions for Affordable Mass Production
Gu H., Kong Y., Huang D., Wang Y., Raghavan V., Wang J.
Narrative Review, published in Compr Rev Food Sci Food Saf (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Compr Rev Food Sci Food Saf (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40635127
- PMCID
- PMC12241508
- DOI
- 10.1111/1541-4337.70221
- Citations
- 9
Abstract (original English)
As the global population grows and meat consumption increases, the demand for sustainable and efficient food systems becomes urgent. Cultured meat (CM) has emerged as a promising alternative to conventional meat, offering potential benefits in environmental conservation, resource efficiency, and animal welfare. Although the cost of CM has dropped dramatically-from $2.3 million/kg for the first cultured beef burger to $63/kg-it remains prohibitively expensive and confined to small-scale production. Recent advancements in areas, such as cell density, cell doubling times, and bioreactor efficiency, have shown promise in further reducing costs. Thus, transformative innovations in all aspects of CM production will contribute to achieving price parity with conventional meat. This review explores the four core technologies underpinning CM production: cell line development, serum-free media, scaffold fabrication, and bioreactor design, with a focus on achieving economical, large-scale production through their interdependence and integration. These technologies converge around three key breakthroughs: engineering genetically stable, highly expandable, and functionalized cell lines to minimize reliance on tissue sampling and expensive growth factors; utilizing plant-based substitutes and recombinant protein alternatives to reduce the costs of media and scaffolds while enhancing biocompat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.